Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE
Perumal, Jai, Fox, Robert J., Balabanov, Roumen, Balcer, Laura J., Galetta, Steven, Makh, Shavy, Santra, Sourav, Hotermans, Christophe, Lee, LilyVolume:
19
Language:
english
Journal:
BMC Neurology
DOI:
10.1186/s12883-019-1337-z
Date:
December, 2019
File:
PDF, 1024 KB
english, 2019